X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs GLENMARK PHARMA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES GLENMARK PHARMA PIRAMAL ENTERPRISES/
GLENMARK PHARMA
 
P/E (TTM) x 36.0 13.6 263.6% View Chart
P/BV x 3.6 3.8 93.8% View Chart
Dividend Yield % 0.7 0.3 204.1%  

Financials

 PIRAMAL ENTERPRISES   GLENMARK PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-16
GLENMARK PHARMA
Mar-16
PIRAMAL ENTERPRISES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0651,262 84.4%   
Low Rs805672 119.9%   
Sales per share (Unadj.) Rs383.0270.6 141.6%  
Earnings per share (Unadj.) Rs55.124.9 221.4%  
Cash flow per share (Unadj.) Rs74.134.4 215.2%  
Dividends per share (Unadj.) Rs17.502.00 875.0%  
Dividend yield (eoy) %1.90.2 904.7%  
Book value per share (Unadj.) Rs719.9151.3 475.7%  
Shares outstanding (eoy) m172.56282.16 61.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.43.6 68.3%   
Avg P/E ratio x17.038.9 43.7%  
P/CF ratio (eoy) x12.628.1 44.9%  
Price / Book Value ratio x1.36.4 20.3%  
Dividend payout %31.88.0 395.1%   
Avg Mkt Cap Rs m161,344272,778 59.1%   
No. of employees `0003.810.0 37.7%   
Total wages/salary Rs m16,89813,782 122.6%   
Avg. sales/employee Rs Th17,472.67,614.9 229.5%   
Avg. wages/employee Rs Th4,466.91,374.8 324.9%   
Avg. net profit/employee Rs Th2,512.8700.2 358.9%   
INCOME DATA
Net Sales Rs m66,09976,340 86.6%  
Other income Rs m2,425356 680.6%   
Total revenues Rs m68,52476,696 89.3%   
Gross profit Rs m18,72314,172 132.1%  
Depreciation Rs m3,2742,691 121.7%   
Interest Rs m9,3881,789 524.8%   
Profit before tax Rs m8,48510,048 84.4%   
Minority Interest Rs m30-   
Prior Period Items Rs m1,5930-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,0323,028 34.1%   
Profit after tax Rs m9,5067,019 135.4%  
Gross profit margin %28.318.6 152.6%  
Effective tax rate %12.230.1 40.3%   
Net profit margin %14.49.2 156.4%  
BALANCE SHEET DATA
Current assets Rs m47,48859,096 80.4%   
Current liabilities Rs m104,36240,018 260.8%   
Net working cap to sales %-86.025.0 -344.3%  
Current ratio x0.51.5 30.8%  
Inventory Days Days4175 54.2%  
Debtors Days Days51119 42.9%  
Net fixed assets Rs m26,53239,075 67.9%   
Share capital Rs m345282 122.3%   
"Free" reserves Rs m114,02430,281 376.5%   
Net worth Rs m124,22142,703 290.9%   
Long term debt Rs m75,81224,873 304.8%   
Total assets Rs m308,356111,026 277.7%  
Interest coverage x1.96.6 28.8%   
Debt to equity ratio x0.60.6 104.8%  
Sales to assets ratio x0.20.7 31.2%   
Return on assets %6.17.9 77.2%  
Return on equity %7.716.4 46.6%  
Return on capital %10.017.5 56.9%  
Exports to sales %17.243.3 39.7%   
Imports to sales %6.67.4 88.9%   
Exports (fob) Rs m11,36233,044 34.4%   
Imports (cif) Rs m4,3645,672 76.9%   
Fx inflow Rs m14,43536,945 39.1%   
Fx outflow Rs m5,18361,066 8.5%   
Net fx Rs m9,253-24,122 -38.4%   
CASH FLOW
From Operations Rs m-67,7733,449 -1,965.3%  
From Investments Rs m-8,768-8,802 99.6%  
From Financial Activity Rs m76,1996,986 1,090.7%  
Net Cashflow Rs m-342934 -36.7%  

Share Holding

Indian Promoters % 52.9 48.3 109.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 6.9 58.0%  
FIIs % 26.6 34.4 77.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 10.5 157.1%  
Shareholders   93,274 56,727 164.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  AJANTA PHARMA  UNICHEM LAB  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Recovery of Global Markets, Apex Frozen Food IPO & Cues to Watch Out Today(Pre-Open)

Indian stock markets remained range-bound in lacklustre trade on Tuesday as market participants kept to the sidelines in the absence of clear triggers.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Aug 22, 2017 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - CIPLA COMPARISON

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS